Managing Infusion Hypersensitivity Reactions with Intravenous Antihistamines
Recorded On: 06/15/2022
Management of hypersensitivity infusion reactions (IRs) with H1-antihistamine premedication and/or treatment is recommended for several biologics and chemotherapies used in infusion centers. The sole second-generation intravenous H1-antihistamine recommended is cetirizine. In this session, the presenter will review key clinical data available with IV cetirizine as well as clinical profiles of first- and second-generation H1 antihistamines used to manage infusion reactions.
Learning Objectives: At the conclusion of this webinar, learners will be able to:
• Explain various infusion reactions and antihistamine use
• Determine infusion reactions requiring a H1-antihistamine to treat a reaction or to prevent future reactions
• Describe the use of IV H1-antihistamines
• Determine which treatment options are the most appropriate for certain patients
Ryan Haumschild, PharmD, MS, MBA
Ryan Haumschild, PharmD, MS, MBA, is an experienced director of pharmacy, overseeing profit and loss responsibility, pharmacy operations, clinical services, formulary management, payer and health plan contracting, and medication use at the Winship Cancer Institute at Emory University, one of the nation’s largest academic integrated delivery networks and Georgia’s only National Cancer Institute (NCI)–designated comprehensive cancer center. Dr. Haumschild provides strategic direction on oncology and nononcology disease states, on infusion and specialty pharmacy services, and on the expansion of clinical services through treatment pathway development. He currently serves as an editorial board member at the American Journal of Managed Care® (AJMC®) and as a board member for the Institute of Safe Medication Practices (ISMP) and for the Center for Biosimilars, and was recently recognized as 40 under 40 by three separate organizations: University of Florida, Atlanta Business Chronicle, and Association for Value-Based Cancer Care.
CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.
Contact Hours: This session has been approved for 1 contact hour
Expiration date for receipt of contact hours: June 15, 2025
To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.
The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.